Identification of cytosolic phosphodiesterases in the erythrocyte: A possible role for PDE5

Medical Science Monitor

Volumn 17, Issue 5, 2011, Pages

  Adderley, Shaquria P ^a   Thuet, Kelly M ^a   Sridharan, Meera ^a   Bowles, Elizabeth A ^a   Stephenson, Alan H ^a   Ellsworth, Mary L ^a   Sprague, Randy S ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CGMP; Isoproterenol; PDE5; Red blood cell; Zaprinast

Indexed keywords

CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 2; ISOPRENALINE; LIFICIGUAT; NITRIC OXIDE DONOR; PHOSPHODIESTERASE; PHOSPHODIESTERASE 3A; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; SPERMINE DERIVATIVE; UNCLASSIFIED DRUG; ZAPRINAST;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOSOL; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME RELEASE; ERYTHROCYTE; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN FUNCTION; RECEPTOR AFFINITY; WESTERN BLOTTING;

EID: 79955939678     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.881763     Document Type: Article

References (53)

1. Olearczyk JJ, Stephenson AH, Lonigro AJ, Sprague RS: Receptormediated activation of the heterotrimeric G-protein Gs results in ATP release from erythrocytes. Med Sci Monit, 2001; 7: 669-74
2. Sprague RS, Bowles EA, Hanson MS et al: Prostacyclin analogs stimulate receptor-mediated cAMP synthesis and ATP release from rabbit and human erythrocytes. Microcirculation, 2008; 15: 461-71
3. Ellsworth ML: Red blood cell-derived ATP as a regulator of skeletal muscle perfusion. Med Sci Sports Exerc, 2004; 36: 35-41
4. Sprague RS, Ellsworth ML, Stephenson AH, Lonigro AJ: ATP: the red blood cell link to NO and local control of the pulmonary circulation. Am J Physiol, 1996; 271: H2717-22
5. Ellsworth ML, Ellis CG, Goldman D et al: Erythrocytes: oxygen sensors and modulators of vascular tone. Physiology (Bethesda), 2009; 24: 107-16
6. Sprague RS, Hanson MS, Achilleus D et al: Rabbit erythrocytes release ATP and dilate skeletal muscle arterioles in the presence of reduced oxygen tension. Pharmacol Rep, 2009; 61: 183-90
7. Zaccolo M, Di Benedetto G, Lissandron V et al: Restricted diffusion of a freely diffusible second messenger: mechanisms underlying compartmentalized cAMP signalling. Biochem Soc Trans, 2006; 34: 495-97
8. Zaccolo M, Movsesian MA: cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ Res, 2007; 100: 1569-78
9. Zaccolo M, Pozzan T: Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science, 2002; 295: 1711-15
10. Bender AT, Beavo JA: Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev, 2006; 58: 488-520
11. Conti M, Beavo J: Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem, 2007; 76: 481-511
12. Baillie GS: Compartmentalized signalling: spatial regulation of cAMP by the action of compartmentalized phosphodiesterases. The FEBS Journal, 2009; 276: 1790-99
13. M, Zaccolo M: A complex phosphodiesterase system controls beta-adrenoceptor signalling in cardiomyocytes. Biochem Soc Trans, 2006' 34: 510-11
14. Adderley SP, Dufaux EA, Sridharan M et al: Iloprost- and isoproterenol- induced increases in cAMP are regulated by different phosphodiesterases in erythrocytes of both rabbits and humans. Am J Physiol Heart Circ Physiol, 2009; 296: H1617-24
15. Adderley SP, Sridharan M, Bowles EA et al: Protein Kinase A and C regualte receptor-mediated increases in cAMP in reabbit erythrocytyes. Am J Physiol Heart Circ Physiol, 2009; 298: H587-93
16. Hanson MS, Stephenson AH, Bowles EA et al: Phosphodiesterase 3 is present in rabbit and human erythrocytes and its inhibition potentiates iloprost-induced increases in cAMP. Am J Physiol Heart Circ Physiol, 2008; 295: H786-93
17. Bolger GB, Erdogan S, Jones RE et al: Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene. Biochem J, 1997; 328 (Pt 2): 539-48
18. Elbatarny HS, Maurice DH: Leptin-mediated activation of human platelets: involvement of a leptin receptor and phosphodiesterase 3A-containing cellular signaling complex. Am J Physiol Endocrinol Metab, 2005; 289: E695-702
19. Li Y, Li H, Liu X et al: Regulation of amygdalar PKA by beta-arrestin-2/ phosphodiesterase-4 complex is critical for fear conditioning. Proc Natl Acad Sci USA, 2009; 106: 21918-23
20. Sasseville M, Cote N, Vigneault C et al: 3'5'-cyclic adenosine monophosphate- dependent up-regulation of phosphodiesterase type 3A in porcine cumulus cells. Endocrinology, 2007; 148: 1858-67
21. Whitaker CM, Beaumont E, Wells MJ et al: Rolipram attenuates acute oligodendrocyte death in the adult rat ventrolateral funiculus following contusive cervical spinal cord injury. Neuroscience letters, 2008; 438: 200-4
22. Zhang W, Colman RW: Thrombin regulates intracellular cyclic AMP concentration in human platelets through phosphorylation/activation of phosphodiesterase 3A. Blood, 2007; 110: 1475-82
23. Delpy E, Coste H, Gouville AC: Effects of cyclic GMP elevation on isoprenaline- induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: role of phosphodiesterase 3. Br J Pharmacol, 1996; 119: 471-78
24. Liu XM, Peyton KJ, Mendelev NN et al: YC-1 stimulates the expression of gaseous monoxide-generating enzymes in vascular smooth muscle cells. Mol Pharmacol, 2009; 75: 208-17
25. Dunkern TR, Hatzelmann A: The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5. Cell Signal, 2005; 17: 331-39
26. Hagiwara M, Endo T, Hidaka H: Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle. Biochem Pharmacol, 1984; 33: 453-57
27. Kotera J, Fujishige K, Akatsuka H et al: Novel alternative splice variants of cGMP-binding cGMP-specific phosphodiesterase. J Biol Chem, 1998; 273: 26982-90
28. Petrov V, Fagard R, Lijnen P: Human erythrocytes contain Ca2+, calmodulin- dependent cyclic nucleotide phosphodiesterase which is involved in the hydrolysis of cGMP. Methods Find Exp Clin Pharmacol, 1998; 20: 387-93
29. Ziolo MT, Lewandowski SJ, Smith JM et al: Inhibition of cyclic GMP hydrolysis with zaprinast reduces basal and cyclic AMP-elevated L-type calcium current in guinea-pig ventricular myocytes. Br J Pharmacol, 2003; 138: 986-94
30. Bruss MD, Richter W, Horner K et al: Critical role of PDE4D in beta2- adrenoceptor-dependent cAMP signaling in mouse embryonic fibroblasts. J Biol Chem, 2008; 283: 22430-42
31. Xiang Y, Naro F, Zoudilova M et al: Phosphodiesterase 4D is required for beta2 adrenoceptor subtype-specific signaling in cardiac myocytes. Proc Natl Acad Sci USA, 2005; 102: 909-14
32. D'Sa C, Tolbert LM, Conti M, Duman RS: Regulation of cAMP-specific phosphodiesterases type 4B and 4D (PDE4) splice variants by cAMP signaling in primary cortical neurons. J Neurochem, 2002; 81: 745-57
33. Hunter RW, Mackintosh C, Hers I: Protein kinase C-mediated phosphorylation and activation of PDE3A regulate cAMP levels in human platelets. J Biol Chem, 2009; 284: 12339-48
34. Sun B, Li H, Shakur Y et al: Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice. Cell Signal, 2007; 19: 1765-71
35. Hambleton R, Krall J, Tikishvili E et al: Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium. J Biol Chem, 2005; 280: 39168-74
36. Kasuya J, Goko H, Fujita-Yamaguchi Y: Multiple transcripts for the human cardiac form of the cGMP-inhibited cAMP phosphodiesterase. J Biol Chem, 1995; 270: 14305-12
37. Wechsler J, Choi YH, Krall J et al: Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes. J Biol Chem, 2002; 277: 38072-78
38. Degerman E, Moos M Jr, Rascon A et al: Single-step affinity purification, partial structure and properties of human platelet cGMP inhibited cAMP phosphodiesterase. Biochim Biophys Acta, 1994; 1205: 189-98
39. Petrov V, Amery A, Lijnen P: Role of cyclic GMP in atrial-natriureticpeptide stimulation of erythrocyte Na+/H+ exchange. Eur J Biochem, 1994; 221: 195-99
40. Petrov V, Lijnen P: Regulation of human erythrocyte Na+/H+ exchange by soluble and particulate guanylate cyclase. Am J Physiol, 1996; 271: C1556-64
41. Maurice DH: Dynamic regulation of cAMP signaling by cGMP in the cardiovascular system: roles of phosphodiesterase 2 and phosphodiesterase 3 enzymes. Proceedings of the Western Pharmacology Society, 2003; 46: 32-36
42. Mullershausen F, Friebe A, Feil R et al: Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling. J Cell Biol, 2003; 160: 719-27
43. Sebkhi A, Strange JW, Phillips SC et al: Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation, 2003; 107: 3230-35
44. Sandner P, Hutter J, Tinel H et al: PDE5 inhibitors beyond erectile dysfunction. Int J Impot Res, 2007; 19: 533-43
45. Gustafsson AB, Brunton LL: Attenuation of cAMP accumulation in adult rat cardiac fibroblasts by IL-1beta and NO: role of cGMP-stimulated PDE2. Am J Physiol Cell Physiol, 2002; 283: C463-71
46. Meyer RB Jr, Miller JP: Analogs of cyclic AMP and cyclic GMP: general methods of synthesis and the relationship of structure to enzymic activity. Life Sci, 1974; 14: 1019-40
47. Castro LR, Verde I, Cooper DM, Fischmeister R: Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation, 2006; 113: 2221-28
48. Mulsch A, Bauersachs J, Schafer A et al: Effect of YC-1, an NOindependent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br J Pharmacol, 1997; 120: 681-89
49. Hwang TL, Hung HW, Kao SH et al: Soluble guanylyl cyclase activator YC-1 inhibits human neutrophil functions through a cGMP-independent but cAMP-dependent pathway. Mol Pharmacol, 2003; 64: 1419-27
50. Galle J, Zabel U, Hubner U et al: Effects of the soluabel guanylyl cyclase activator, YC-1, on vascualr tone, cyclic GMP levels and phosphodiesterase activity. Br J Pharmacol, 1999; 127: 195-203
51. Sane DC, Bielawska A, Greenberg CS, Hannun YA: Cyclic GMP analogs inhibit gamma thrombin-induced arachidonic acid release in human platelets. Biochem Biophys Res Commun, 1989; 165: 708-14
52. Ghofrani HA, Wiedemann R, Rose F et al: Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med, 2002; 136: 515-22
53. Wilkens H, Guth A, Konig J et al: Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation, 2001; 104: 1218-22